{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:58:00Z","timestamp":1792853880593,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of anabolic androgenic steroids (AAS) and associated image and performance enhancing drugs (IPEDs) is now a global phenomenon. There is a need to develop evidence to support the development of interventions to prevent the commencement of use, to minimise the potential harms or to support those in their cessation of use. While the United Kingdom (UK) is no exception to this issue, its public health and legislative response to the phenomenon differs to other countries and requires the examination of research specific to the UK. Therefore, a scoping review has been conducted to examine the recent relevant literature to help inform the development and evaluation of effective interventions to reduce the harmful use of IPEDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search strategy was developed for multiple bibliographic databases, supported by and iterative citation searching process and complimented by expert input from the Anabolic Steroid UK Network. Research conducted by or UK academics or within the UK were eligible, if published in the previous five years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total 87 eligible outputs were identified, including 26 review articles, 25 qualitative papers and 24 quantitative papers. together with small numbers of clinical studies\/case reports (6) and commentaries\/correspondence (6). The most common topics of research were public health, treatment and harm reduction (41), followed by studies focusing on epidemiology, sub-groups of people using IPEDs and motivations for use (34). The studies illustrated the diverse populations of people who use a range of enhancement drugs including concomitant psychoactive drug use. A number of papers focused on blood borne viruses and associated issues, while others reported on the uptake of needle and syringe programmes. No effectiveness evaluations related to any aspect of treatment, harm reduction or other intervention were published during study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is a need for the development of effectiveness evaluations of current interventions and any future service provision for people using image and performance enhancing drugs. While there have been no studies of this nature to date, this review illustrates the rich data that has been gathered through diverse methodologies, that will assist in the development of future effectiveness evaluations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-021-00550-z","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T17:04:48Z","timestamp":1634490288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Generating evidence on the use of Image and performance enhancing drugs in the UK: results from a scoping review and expert consultation by the Anabolic Steroid UK network"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5319-6885","authenticated-orcid":false,"given":"Jim","family":"McVeigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Hearne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Boardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Ralphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Claire","family":"Van Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"key":"550_CR1","doi-asserted-by":"publisher","DOI":"10.4324\/9781315148328","volume-title":"Human enhancement drugs","author":"K Van de Ven","year":"2019","unstructured":"Van de Ven K, Mulrooney KJ, McVeigh J. Human enhancement drugs. 1st ed. Abigdon: Routledge; 2019.","edition":"1"},{"key":"550_CR2","volume-title":"Human enhancement drugs: the emerging challenges to public health","author":"M Evans-Brown","year":"2012","unstructured":"Evans-Brown M, McVeigh J, Perkins C, Bellis M. Human enhancement drugs: the emerging challenges to public health. Liverpool: North West Public Health Observatory; 2012."},{"issue":"3","key":"550_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.20882\/adicciones.88","volume":"24","author":"J McVeigh","year":"2012","unstructured":"McVeigh J, Evans-Brown M, Bellis MA. Human enhancement drugs and the pursuit of perfection. Adicciones. 2012;24(3):185\u201390.","journal-title":"Adicciones"},{"issue":"3","key":"550_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/09687637.2016.1245713","volume":"24","author":"J McVeigh","year":"2017","unstructured":"McVeigh J, Begley E. Anabolic steroids in the UK: an increasing issue for public health. Drugs Educ Prevent Policy. 2017;24(3):278\u201385.","journal-title":"Drugs Educ Prevent Policy"},{"issue":"3","key":"550_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.peh.2015.10.004","volume":"3","author":"R Coomber","year":"2014","unstructured":"Coomber R, Pavlidis A, Santos GH, Wilde M, Schmidt W, Redshaw C. The supply of steroids and other performance and image enhancing drugs (PIEDs) in one English city: fakes, counterfeits, supplier trust, common beliefs and access. Perform Enhanc Health. 2014;3(3):135\u201344.","journal-title":"Perform Enhanc Health"},{"key":"550_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drugpo.2016.11.005","volume":"40","author":"G Hanley Santos","year":"2017","unstructured":"Hanley Santos G, Coomber R. The risk environment of anabolic-androgenic steroid users in the UK: examining motivations, practices and accounts of use. Int J Drug Policy. 2017;40:35\u201343.","journal-title":"Int J Drug Policy"},{"key":"550_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drugpo.2019.01.019","volume":"67","author":"M Salinas","year":"2019","unstructured":"Salinas M, Floodgate W, Ralphs R. Polydrug use and polydrug markets amongst image and performance enhancing drug users: implications for harm reduction interventions and drug policy. Int J Drug Policy. 2019;67:43\u201351.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"550_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/MED.0000000000000403","volume":"25","author":"D Sagoe","year":"2018","unstructured":"Sagoe D, Pallesen S. Androgen abuse epidemiology. Curr Opin Endocrinol Diabetes Obes. 2018;25(3):185\u201394.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"550_CR9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s11469-019-00217-8","volume":"19","author":"E Hearne","year":"2020","unstructured":"Hearne E, Wazaify M, Van Hout MC, Atkinson A, McVeigh J. Anabolic-androgenic steroid use in the Eastern Mediterranean region: a scoping review of extant empirical literature. Int J Mental Health Addict. 2020;19:1162\u201389.","journal-title":"Int J Mental Health Addict"},{"issue":"9","key":"550_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3109\/10826084.2014.912062","volume":"49","author":"FR de Siqueira Nogueira","year":"2014","unstructured":"de Siqueira Nogueira FR, de Freitas BA, de Oliveira CVC, Vieira TI, Beniz Gouveia RL. Anabolic\u2013androgenic steroid use among Brazilian bodybuilders. Subst Use Misuse. 2014;49(9):1138\u201345.","journal-title":"Subst Use Misuse"},{"issue":"9","key":"550_CR11","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3109\/10826084.2014.903750","volume":"49","author":"OSC Abrahin","year":"2014","unstructured":"Abrahin OSC, de Sousa EC, Santos AM. Prevalence of the use of anabolic-androgenic steroids in Brazil: A systematic review. Subst Use Misuse. 2014;49(9):1156\u201362.","journal-title":"Subst Use Misuse"},{"key":"550_CR12","unstructured":"Druglink. ACMD recommends new controls on steroids. Druglink. 1993;September\/October 1993."},{"key":"550_CR13","unstructured":"ACMD. Consideration of the Anabolic Steroids. London (UK); 2010."},{"issue":"ARTN 19","key":"550_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1477-7517-11-19","volume":"11","author":"A Kimergard","year":"2014","unstructured":"Kimergard A, McVeigh J. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study. Harm Reduct J. 2014;11(ARTN 19):19.","journal-title":"Harm Reduct J"},{"issue":"3","key":"550_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/09687637.2016.1245713","volume":"24","author":"J McVeigh","year":"2017","unstructured":"McVeigh J, Begley E. Anabolic steroids in the UK: an increasing issue for public health. Drug-Educ Prev Polic. 2017;24(3):278\u201385.","journal-title":"Drug-Educ Prev Polic"},{"issue":"6","key":"550_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1055\/s-2007-972873","volume":"17","author":"F Hartgens","year":"1996","unstructured":"Hartgens F, Kuipers H, Wijnen JAG, Keizer HA. Body composition, cardiovascular risk factors and liver function in long term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal. Int J Sports Med. 1996;17(6):429\u201333.","journal-title":"Int J Sports Med"},{"issue":"21","key":"550_CR17","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.116.026945","volume":"135","author":"AL Baggish","year":"2017","unstructured":"Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991\u20132002.","journal-title":"Circulation"},{"issue":"6","key":"550_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.scispo.2018.05.003","volume":"33","author":"PJ Angell","year":"2018","unstructured":"Angell PJ, Green DJ, Lord R, Gaze D, Whyte G, George KP. Acute cardiovascular responses to resistance exercise in anabolic steroids users: a preliminary investigation. Sci Sports. 2018;33(6):339\u201346.","journal-title":"Sci Sports"},{"issue":"2","key":"550_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11154-020-09616-y","volume":"22","author":"D McCullough","year":"2020","unstructured":"McCullough D, Webb R, Enright KJ, Lane KE, McVeigh J, Stewart CE, et al. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Rev Endocr Metab Disord. 2020;22(2):389\u2013405.","journal-title":"Rev Endocr Metab Disord"},{"key":"550_CR20","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/add.14629","volume":"114","author":"LE Hauger","year":"2019","unstructured":"Hauger LE, Westlye LT, Fjell AM, Walhovd KB, Bjornebekk A. Structural brain characteristics of anabolic-androgenic steroid dependence in men. Addiction. 2019;114:1405\u201315.","journal-title":"Addiction"},{"issue":"3","key":"550_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/MED.0000000000000404","volume":"25","author":"G Kanayama","year":"2018","unstructured":"Kanayama G, Kaufman MJ, Pope HG. Public health impact of androgens. Curr Opin Endocrinol. 2018;25(3):218\u201323.","journal-title":"Curr Opin Endocrinol"},{"issue":"3","key":"550_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1210\/er.2013-1058","volume":"35","author":"HG Pope Jr","year":"2014","unstructured":"Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341\u201375.","journal-title":"Endocr Rev"},{"key":"550_CR23","doi-asserted-by":"publisher","unstructured":"Harvey O, Parrish M, van Teijlingen E, Trenoweth S. Libido as a motivator for starting and restarting non-prescribed anabolic androgenic steroid use among men: a mixed-methods study. Drug-Educ Prev Polic. 2021. https:\/\/doi.org\/10.1080\/09687637.2021.1882940.","DOI":"10.1080\/09687637.2021.1882940"},{"key":"550_CR24","doi-asserted-by":"publisher","unstructured":"Chegeni R, Pallesen S, McVeigh J, Sagoe D. Anabolic-androgenic steroid administration increases self-reported aggression in healthy males: a systematic review and meta-analysis of experimental studies. Psychopharmacology (Berl). 2021. https:\/\/doi.org\/10.1007\/s00213-021-05818-7.","DOI":"10.1007\/s00213-021-05818-7"},{"key":"550_CR25","doi-asserted-by":"crossref","unstructured":"Pope HG, Jr., Kanayama G, Hudson JI, Kaufman MJ. Review article: anabolic-androgenic steroids, violence, and crime: two cases and literature review. Am J Addict. 2021;30(5):423\u201332.","DOI":"10.1111\/ajad.13157"},{"key":"550_CR26","doi-asserted-by":"publisher","first-page":"108604","DOI":"10.1016\/j.drugalcdep.2021.108604","volume":"221","author":"LE Hauger","year":"2021","unstructured":"Hauger LE, Havnes IA, Jorstad ML, Bjornebekk A. Anabolic androgenic steroids, antisocial personality traits, aggression and violence. Drug Alcohol Depend. 2021;221:108604.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"550_CR27","doi-asserted-by":"publisher","first-page":"155798832096653","DOI":"10.1177\/1557988320966536","volume":"14","author":"AK Bonnecaze","year":"2020","unstructured":"Bonnecaze AK, O\u2019Connor T, Aloi JA. Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men. Am J Mens Health. 2020;14(6):1557988320966536.","journal-title":"Am J Mens Health"},{"key":"550_CR28","volume-title":"Image and performance enhancing drugs: 2016 National Survey Results","author":"E Begley","year":"2017","unstructured":"Begley E, McVeigh J, Hope V, Bates G, Glass R, Campbell J, et al. Image and performance enhancing drugs: 2016 National Survey Results. Liverpool: Liverpool John Moores University; 2017."},{"key":"550_CR29","volume-title":"Humam enhancement drugs","author":"V Hope","year":"2019","unstructured":"Hope V, Iversen J. Infections and risk among people who use image and performance enhancing drugs. In: Van de Ven K, Mulrooney K, McVeigh J, editors. Humam enhancement drugs. Abingdon: Routledge; 2019."},{"issue":"9","key":"550_CR30","doi-asserted-by":"publisher","first-page":"e003207","DOI":"10.1136\/bmjopen-2013-003207","volume":"3","author":"VD Hope","year":"2013","unstructured":"Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergard A, et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 2013;3(9):e003207.","journal-title":"BMJ Open"},{"issue":"3","key":"550_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/QAI.0000000000000835","volume":"71","author":"VD Hope","year":"2016","unstructured":"Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, et al. Risk of HIV and hepatitis B and C over time among men who inject image and performance enhancing drugs in england and wales: results from cross-sectional prevalence surveys, 1992\u20132013. J Acquir Immune Defic Syndr. 2016;71(3):331\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"550_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1017\/S0950268814000727","volume":"143","author":"VD Hope","year":"2015","unstructured":"Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergard A, et al. Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiol Infect. 2015;143(1):132\u201340.","journal-title":"Epidemiol Infect"},{"issue":"8","key":"550_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1592\/phco.31.8.757","volume":"31","author":"EJ Ip","year":"2011","unstructured":"Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011;31(8):757\u201366.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"550_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/09595230802392568","volume":"27","author":"B Larance","year":"2008","unstructured":"Larance B, Degenhardt L, Copeland J, Dillon P. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. Drug Alcohol Rev. 2008;27(6):679\u201386.","journal-title":"Drug Alcohol Rev"},{"key":"550_CR35","doi-asserted-by":"crossref","unstructured":"Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Positive and negative side effects of androgen abuse. The HAARLEM study: a one year prospective cohort study in 100 men. Scand J Med Sci Sports. 2020;30(3):531\u201339.","DOI":"10.1111\/sms.13592"},{"key":"550_CR36","doi-asserted-by":"publisher","first-page":"110771","DOI":"10.1016\/j.forsciint.2021.110771","volume":"322","author":"N Fabresse","year":"2021","unstructured":"Fabresse N, Gheddar L, Kintz P, Knapp A, Larabi IA, Alvarez JC. Analysis of pharmaceutical products and dietary supplements seized from the black market among bodybuilders. Forensic Sci Int. 2021;322:110771.","journal-title":"Forensic Sci Int"},{"key":"550_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jpba.2015.03.018","volume":"111","author":"SH Cho","year":"2015","unstructured":"Cho SH, Park HJ, Lee JH, Do JA, Heo S, Jo JH, et al. Determination of anabolic-androgenic steroid adulterants in counterfeit drugs by UHPLC-MS\/MS. J Pharm Biomed Anal. 2015;111:138\u201346.","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"550_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/dta.74","volume":"1","author":"M Evans-Brown","year":"2009","unstructured":"Evans-Brown M, Kimergard A, McVeigh J. Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market. Drug Test Anal. 2009;1(7):323\u20136.","journal-title":"Drug Test Anal"},{"key":"550_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.steroids.2018.07.002","volume":"138","author":"MVD Ribeiro","year":"2018","unstructured":"Ribeiro MVD, Boralle N, Felippe LG, Pezza HR, Pezza L. H-1 NMR determination of adulteration of anabolic steroids in seized drugs. Steroids. 2018;138:47\u201356.","journal-title":"Steroids"},{"issue":"ARTN 12","key":"550_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13011-015-0006-5","volume":"10","author":"D Sagoe","year":"2015","unstructured":"Sagoe D, McVeigh J, Bjornebekk A, Essilfie MS, Andreassen CS, Pallesen S. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis. Subst Abuse Treat Prev Policy. 2015;10(ARTN 12):12.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"5","key":"550_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/14659890903224383","volume":"14","author":"M Evans-Brown","year":"2009","unstructured":"Evans-Brown M, McVeigh J. Injecting human growth hormone as a performance-enhancing drug-perspectives from the United Kingdom. J Subst Use. 2009;14(5):267\u201388.","journal-title":"J Subst Use"},{"issue":"2","key":"550_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0091450920919456","volume":"47","author":"R Zahnow","year":"2020","unstructured":"Zahnow R, McVeigh J, Bates G, Winstock AR. Motives and correlates of anabolic-androgenic steroid use with stimulant polypharmacy. Contemp Drug Probl. 2020;47(2):118\u201335.","journal-title":"Contemp Drug Probl"},{"key":"550_CR43","doi-asserted-by":"publisher","DOI":"10.4324\/9781003018438","volume-title":"Gym culture, identity and performance-enhancing drugs: tracing a typology of steroid use","author":"AV Christiansen","year":"2020","unstructured":"Christiansen AV. Gym culture, identity and performance-enhancing drugs: tracing a typology of steroid use. Oxon: Routledge; 2020."},{"issue":"3","key":"550_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/09687637.2016.1231173","volume":"24","author":"AV Christiansen","year":"2016","unstructured":"Christiansen AV, Vinther AS, Liokaftos D. Outline of a typology of men\u2019s use of anabolic androgenic steroids in fitness and strength training environments. Drugs Educ Prevent Policy. 2016;24(3):295\u2013305.","journal-title":"Drugs Educ Prevent Policy"},{"key":"550_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugpo.2018.02.022","volume":"55","author":"R Zahnow","year":"2018","unstructured":"Zahnow R, McVeigh J, Bates G, Hope V, Kean J, Campbell J, et al. Identifying a typology of men who use anabolic androgenic steroids (AAS). Int J Drug Policy. 2018;55:105\u201312.","journal-title":"Int J Drug Policy"},{"key":"550_CR46","doi-asserted-by":"publisher","unstructured":"Havnes IA, Jorstad ML, Innerdal I, Bjornebekk A. Anabolic-androgenic steroid use among women\u2014A qualitative study on experiences of masculinizing, gonadal and sexual effects. Int J Drug Policy. 2020:102876. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102876.","DOI":"10.1016\/j.drugpo.2020.102876"},{"key":"550_CR47","unstructured":"McVeigh J. Application Development Award Image and Performance Enhancing Drugs (IPEDs): Assessment of available intelligence and research gaps to inform intervention evaluation: NIHR; 2021 [Available from: https:\/\/www.journalslibrary.nihr.ac.uk\/programmes\/phr\/NIHR132730\/#\/."},{"key":"550_CR48","doi-asserted-by":"publisher","unstructured":"Bates G, Shepherd S, McVeigh J. Harm reduction strategies for androgen users: providing appropriate support and improving engagement with healthcare. Curr Opin Endocrinol Diabetes Obes. 2021. https:\/\/doi.org\/10.1097\/MED.0000000000000676.","DOI":"10.1097\/MED.0000000000000676"},{"issue":"1","key":"550_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"issue":"2","key":"550_CR50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/wvn.12144","volume":"13","author":"H Khalil","year":"2016","unstructured":"Khalil H, Peters M, Godfrey CM, McInerney P, Soares CB, Parker D. An evidence-based approach to scoping reviews. Worldviews Evid Based Nurs. 2016;13(2):118\u201323.","journal-title":"Worldviews Evid Based Nurs"},{"issue":"3","key":"550_CR51","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","volume":"13","author":"MDJ Peters","year":"2015","unstructured":"Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141\u20136.","journal-title":"Int J Evid Based Healthc"},{"issue":"1","key":"550_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(1):69.","journal-title":"Implement Sci"},{"issue":"7","key":"550_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"1","key":"550_CR54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2288-13-48","volume":"13","author":"HML Daudt","year":"2013","unstructured":"Daudt HML, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team\u2019s experience with Arksey and O\u2019Malley\u2019s framework. BMC Med Res Methodol. 2013;13(1):48.","journal-title":"BMC Med Res Methodol"},{"key":"550_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12874-016-0116-4","volume":"16","author":"AC Tricco","year":"2016","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016;16:15.","journal-title":"BMC Med Res Methodol"},{"key":"550_CR56","doi-asserted-by":"publisher","DOI":"10.4324\/9781315148328-17","volume-title":"The supply of image and performance enhancing drugs (IPED) to local non-elite users in England: Resilient traditional and newly emergent methods. Human enhancement drugs","author":"R Coomber","year":"2019","unstructured":"Coomber R, Salinas M. The supply of image and performance enhancing drugs (IPED) to local non-elite users in England: Resilient traditional and newly emergent methods. Human enhancement drugs. Abingdon: Routledge; 2019."},{"key":"550_CR57","doi-asserted-by":"publisher","unstructured":"Germain DJ, Leavey DC, Van Hout PMC, McVeigh PJ. 2,4 dinitrophenol: It's not just for men. Int J Drug Policy. 2020:102987. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102987.","DOI":"10.1016\/j.drugpo.2020.102987"},{"issue":"2","key":"550_CR58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/14659891.2016.1149238","volume":"22","author":"J McVeigh","year":"2017","unstructured":"McVeigh J, Germain J, Van Hout MC. 2,4-Dinitrophenol, the inferno drug: a netnographic study of user experiences in the quest for leanness. J Subst Use. 2017;22(2):131\u20138.","journal-title":"J Subst Use"},{"key":"550_CR59","volume-title":"Human enhancement drugs","author":"J Germain","year":"2019","unstructured":"Germain J, McLean C, Leavey C. One size does not fit all: Tackling the issue of weight-loss drug use. In: van de Ven K, Mulrooney K, McVeigh J, editors. Human enhancement drugs. Abingdon: Routledge; 2019."},{"key":"550_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drugpo.2017.12.012","volume":"52","author":"NP Ainsworth","year":"2018","unstructured":"Ainsworth NP, Vargo EJ, Petroczi A. Being in control? A thematic content analysis of 14 in-depth interviews with 2,4-dinitrophenol users. Int J Drug Policy. 2018;52:106\u201314.","journal-title":"Int J Drug Policy"},{"key":"550_CR61","volume-title":"Human enhancement drugs","author":"MC Van Hout","year":"2019","unstructured":"Van Hout MC, McVeigh J. The use of sunless synthetic tanning products. In: Van de Ven K, Mulrooney K, McVeigh J, editors. Human enhancement drugs. Abingdon: Routledge; 2019."},{"issue":"2","key":"550_CR62","doi-asserted-by":"publisher","first-page":"e227644","DOI":"10.1136\/bcr-2018-227644","volume":"12","author":"BA Dreyer","year":"2019","unstructured":"Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2):e227644. https:\/\/doi.org\/10.1136\/bcr-2018-227644","journal-title":"BMJ Case Rep"},{"key":"550_CR63","volume-title":"Chemically modified bodies","author":"MR Graham","year":"2016","unstructured":"Graham MR, Baker JS, Davies B. Peptide hormones, metformin and new-wave practices and research therapies. In: Hall M, Grogan S, Gough B, editors. Chemically modified bodies. London: Palgrave Macmillan; 2016."},{"issue":"1","key":"550_CR64","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/10826084.2015.1082595","volume":"51","author":"MC Van Hout","year":"2016","unstructured":"Van Hout MC, Hearne E. Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Subst Use Misuse. 2016;51(1):73\u201384.","journal-title":"Subst Use Misuse"},{"issue":"9","key":"550_CR65","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1177\/1359105314568579","volume":"21","author":"M Hall","year":"2016","unstructured":"Hall M, Grogan S, Gough B. Bodybuilders\u2019 accounts of synthol use: The construction of lay expertise online. J Health Psychol. 2016;21(9):1939\u201348.","journal-title":"J Health Psychol"},{"issue":"2","key":"550_CR66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/09687637.2019.1608910","volume":"27","author":"K van de Ven","year":"2019","unstructured":"van de Ven K, Zahnow R, McVeigh J, Winstock A. The modes of administration of anabolic-androgenic steroid (AAS) users: are non-injecting people who use steroids overlooked? Drug Educ Prev Policy. 2019;27(2):131\u20135.","journal-title":"Drug Educ Prev Policy"},{"key":"550_CR67","volume-title":"Human enhancement drugs","author":"ID Boardley","year":"2019","unstructured":"Boardley ID. Licit forms of performance enhancement and possible links with IPED use: Current knowledge and future directions. In: Van de Ven K, Mulrooney K, McVeigh J, editors. Human enhancement drugs. Abingdon: Routledge; 2019."},{"key":"550_CR68","doi-asserted-by":"publisher","unstructured":"Mooney R, Simonato P, Ruparelia R, Roman-Urrestarazu A, Martinotti G, Corazza O. The use of supplements and performance and image enhancing drugs in fitness settings: A exploratory cross-sectional investigation in the United Kingdom. Hum Psychopharmacol Clin Exp. 2017;32:e2619. https:\/\/doi.org\/10.1002\/hup.2619.","DOI":"10.1002\/hup.2619"},{"key":"550_CR69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.peh.2019.100152","volume":"7","author":"LA Turnock","year":"2020","unstructured":"Turnock LA. Inside a steroid \u2018brewing\u2019 and supply operation in South-West England: An \u2018ethnographic narrative case study.\u2019 Perform Enhancem Health. 2020;7:3\u20134.","journal-title":"Perform Enhancem Health"},{"key":"550_CR70","volume-title":"Human enhancement drugs","author":"A Hall","year":"2019","unstructured":"Hall A, Antonopoulos GA. The (online) supply of illicit lifestyle medicines: a criminological study. In: Van de Ven K, Mulrooney K, McVeigh J, editors. Human enhancement drugs. Abingdon: Routledge; 2019."},{"key":"550_CR71","volume-title":"An exploration of evolving forms of access to performance and image enhancing drugs (PIED), and body image, on Gold Coast, Australia, with particular emphasis on how users reconcile their drift into criminality","author":"J Coomber-Moore","year":"2017","unstructured":"Coomber-Moore J. An exploration of evolving forms of access to performance and image enhancing drugs (PIED), and body image, on Gold Coast, Australia, with particular emphasis on how users reconcile their drift into criminality. Essex: University of Essex; 2017."},{"issue":"3\u20134","key":"550_CR72","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12117-017-9304-9","volume":"20","author":"A Hall","year":"2017","unstructured":"Hall A, Koenraadt R, Antonopoulos GA. Illicit pharmaceutical networks in Europe: organising the illicit medicine market in the United Kingdom and the Netherlands. Trends Organ Crime. 2017;20(3\u20134):296\u2013315.","journal-title":"Trends Organ Crime"},{"key":"550_CR73","volume-title":"Fake meds online the internet and the transnational market in illicit pharmaceuticals","author":"A Hall","year":"2016","unstructured":"Hall A, Antonopoulos A. Fake meds online the internet and the transnational market in illicit pharmaceuticals. London: Palgrave Macmillan; 2016."},{"key":"550_CR74","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.drugpo.2017.11.001","volume":"51","author":"J Tay Wee Teck","year":"2018","unstructured":"Tay Wee Teck J, McCann M. Tracking internet interest in anabolic-androgenic steroids using Google Trends. Int J Drug Policy. 2018;51:52\u20135.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"550_CR75","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/1477370816633261","volume":"13","author":"GA Antonopoulos","year":"2016","unstructured":"Antonopoulos GA, Hall A. \u201cGain with no pain\u2019\u2019: anabolic-androgenic steroids trafficking in the UK.\u201d Eur J Criminol. 2016;13(6):696\u2013713.","journal-title":"Eur J Criminol"},{"key":"550_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2017.01.016","volume":"40","author":"C Chatwin","year":"2017","unstructured":"Chatwin C, Measham F, O\u2019Brien K, Sumnall H. New drugs, new directions? Research priorities for new psychoactive substances and human enhancement drugs. Int J Drug Policy. 2017;40:1\u20135.","journal-title":"Int J Drug Policy"},{"key":"550_CR77","doi-asserted-by":"publisher","unstructured":"McVeigh J, Salinas M, Ralphs R. A sentinel population: The public health benefits of monitoring enhanced body builders. Int J Drug Policy. 2020:102890. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102890.","DOI":"10.1016\/j.drugpo.2020.102890"},{"key":"550_CR78","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.peh.2020.100174","volume":"8","author":"J Kotz\u00e9","year":"2020","unstructured":"Kotz\u00e9 J, Richardson A, Antonopoulos GA. Looking \u2018acceptably\u2019 feminine: A single case study of a female bodybuilder\u2019s use of steroids. Perform Enhanc Health. 2020;8:2\u20133.","journal-title":"Perform Enhanc Health"},{"key":"550_CR79","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jflm.2019.03.009","volume":"64","author":"A Richardson","year":"2019","unstructured":"Richardson A, Dixon K, Kean J. Superheroes\u2014Image and performance enhancing drug (IPED) use within the UK, social media and gym culture. J Forensic Leg Med. 2019;64:28\u201330.","journal-title":"J Forensic Leg Med"},{"key":"550_CR80","doi-asserted-by":"publisher","first-page":"101871","DOI":"10.1016\/j.jflm.2019.101871","volume":"68","author":"A Richardson","year":"2019","unstructured":"Richardson A, Antonopoulos GA. Anabolic-androgenic steroids (AAS) users on AAS use: Negative effects, \u201ccode of silence\u201d, and implications for forensic and medical professionals. J Forensic Leg Med. 2019;68:101871.","journal-title":"J Forensic Leg Med"},{"key":"550_CR81","doi-asserted-by":"publisher","unstructured":"Henning A, Andreasson J. \"Yay, Another Lady Starting a Log!\": Women's Fitness Doping and the Gendered Space of an Online Doping Forum. Commun Sport. 2019. https:\/\/doi.org\/10.1177\/2167479519896326.","DOI":"10.1177\/2167479519896326"},{"key":"550_CR82","doi-asserted-by":"crossref","unstructured":"Harris MA, Dunn M, Alwyn T. Symptoms of muscle dysmorphia between users of anabolic androgenic steroids with varying usage and bodybuilding experience. Eur J Health Psychol. 2019;26(1):21\u201324.","DOI":"10.1027\/2512-8442\/a000023"},{"key":"550_CR83","unstructured":"UKAD. Image and performance enhancing drugs. London: UK Anti-Doping; 2019."},{"key":"550_CR84","volume-title":"Drugs in Sport","author":"N Chester","year":"2018","unstructured":"Chester N, McVeigh J. Drug use in society and the impact on the anti-doping movement. In: Mottram DR, Chester N, editors. Drugs in Sport. London: Routledge; 2018."},{"issue":"1","key":"550_CR85","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/tsm2.186","volume":"4","author":"I Whyte","year":"2020","unstructured":"Whyte I, Pattinson E, Leyland S, Soos I, Ling J. Performance and image enhancing drugs use in active military personnel and veterans: A contemporary review. Transl Sports Med. 2020;4(1):72\u201387.","journal-title":"Transl Sports Med"},{"issue":"1\u20132","key":"550_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.peh.2015.11.005","volume":"4","author":"ID Boardley","year":"2016","unstructured":"Boardley ID, Allen N, Simmons A, Laws H. Nutritional, medicinal, and performance enhancing supplementation in dance. Perform Enhanc Health. 2016;4(1\u20132):3\u201311.","journal-title":"Perform Enhanc Health"},{"key":"550_CR87","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.peh.2020.100176","volume":"8","author":"I Cranswick","year":"2020","unstructured":"Cranswick I, Richardson D, Littlewood M, Tod D. \u201cOh take some man-up pills\u201d: A life-history study of muscles, masculinity, and the threat of injury. Perform Enhanc Health. 2020;8:2\u20133.","journal-title":"Perform Enhanc Health"},{"key":"550_CR88","doi-asserted-by":"crossref","unstructured":"Kotze J, Antonopoulos GA. Boosting bodily capital: Maintaining masculinity, aesthetic pleasure and instrumental utility through the consumption of steroids. J Consumer Cult. 2019;21(3):683\u2013700.","DOI":"10.1177\/1469540519846196"},{"issue":"4","key":"550_CR89","doi-asserted-by":"publisher","first-page":"e0213060","DOI":"10.1371\/journal.pone.0213060","volume":"14","author":"O Corazza","year":"2019","unstructured":"Corazza O, Simonato P, Demetrovics Z, Mooney R, van de Ven K, Roman-Urrestarazu A, et al. The emergence of Exercise Addiction, Body Dysmorphic Disorder, and other image-related psychopathological correlates in fitness settings: A cross sectional study. PLoS ONE. 2019;14(4):e0213060.","journal-title":"PLoS ONE"},{"key":"550_CR90","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.psychsport.2018.01.007","volume":"36","author":"ID Boardley","year":"2018","unstructured":"Boardley ID, Smith AL, Mills J, Grix J, Wynne C, Wilkins L. Development of moral disengagement and self-regulatory efficacy assessments relevant to doping in sport and exercise. Psychol Sport Exerc. 2018;36:57\u201370.","journal-title":"Psychol Sport Exerc"},{"issue":"6","key":"550_CR91","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/09687637.2018.1488947","volume":"26","author":"G Bates","year":"2018","unstructured":"Bates G, Tod D, Leavey C, McVeigh J. An evidence-based socioecological framework to understand men\u2019s use of anabolic androgenic steroids and inform interventions in this area. Drugs Educ Prev Policy. 2018;26(6):484\u201392.","journal-title":"Drugs Educ Prev Policy"},{"issue":"9","key":"550_CR92","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1177\/1359105317692145","volume":"24","author":"M Harris","year":"2017","unstructured":"Harris M, Dunn M, Alwyn T. Intrasexual competition as a potential influence on anabolic-androgenic steroid use initiation. J Health Psychol. 2017;24(9):1210\u201320.","journal-title":"J Health Psychol"},{"key":"550_CR93","doi-asserted-by":"crossref","unstructured":"Boardley ID, Smith AL, Mills JP, Grix J, Wynne C. Empathic and Self-Regulatory Processes Governing Doping Behavior. Front Psychol. 2017;8.","DOI":"10.3389\/fpsyg.2017.01495"},{"key":"550_CR94","volume-title":"Chemically modified bodies","author":"D Smith","year":"2016","unstructured":"Smith D, Rutty MC, Olrich TW. Muscle dysmorphia and anabolic-androgenic steroid use. In: Hall M, Grogan S, editors. Chemically modified bodies. London: Palgrave Macmillan; 2016."},{"issue":"2","key":"550_CR95","first-page":"210","volume":"21","author":"HE Joubert","year":"2016","unstructured":"Joubert HE, Melluish S. Considering anabolic androgenic steroid use in relation to non-substance related diagnostic categories with special emphasis on eating disorders: a systematic review. J Subst Use. 2016;21(2):210\u20136.","journal-title":"J Subst Use"},{"issue":"4","key":"550_CR96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.5114\/hpr.2016.61669","volume":"4","author":"MA Harris","year":"2016","unstructured":"Harris MA, Dunn M, Alwyn T. A qualitative exploration of the motivations underlying anabolic-androgenic steroid use from adolescence into adulthood. Health Psychol Rep. 2016;4(4):315\u201320.","journal-title":"Health Psychol Rep"},{"key":"550_CR97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.peh.2019.100154","volume":"7","author":"CW Greenway","year":"2020","unstructured":"Greenway CW, Price C. Muscle dysmorphia and self-esteem in former and current users of anabolic-androgenic steroids. Perform Enhanc Health. 2020;7:3\u20134.","journal-title":"Perform Enhanc Health"},{"issue":"1","key":"550_CR98","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.peh.2018.02.002","volume":"6","author":"CW Greenway","year":"2018","unstructured":"Greenway CW, Price C. A qualitative study of the motivations for anabolic-androgenic steroid use: the role of muscle dysmorphia and self-esteem in long-term users. Perform Enhanc Health. 2018;6(1):12\u201320.","journal-title":"Perform Enhanc Health"},{"key":"550_CR99","doi-asserted-by":"crossref","unstructured":"Coxon J. Hypogonadism persistence after long-term illicit use of anabolic-androgenic steroids. J Sex Med. 2016;13(5):S180-S.","DOI":"10.1016\/j.jsxm.2016.03.238"},{"issue":"2","key":"550_CR100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/joim.12884","volume":"286","author":"JA Mossman","year":"2019","unstructured":"Mossman JA, Pacey AA. The fertility fitness paradox of anabolic-androgenic steroid abuse in men. J Intern Med. 2019;286(2):231\u20132.","journal-title":"J Intern Med"},{"key":"550_CR101","doi-asserted-by":"publisher","unstructured":"Hibbert MP, Brett CE, Porcellato LA, Hope VD. Image and performance enhancing drug use among men who have sex with men and women who have sex with women in the UK. Int J Drug Policy. 2020:102933. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102933.","DOI":"10.1016\/j.drugpo.2020.102933"},{"issue":"1","key":"550_CR102","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/dta.2912","volume":"13","author":"JMX Amaral","year":"2021","unstructured":"Amaral JMX, Padilha MC, Chagas SV, Baker JS, Mullen C, Vieira Neto L, et al. Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids. Drug Test Anal. 2021;13(1):197\u2013202.","journal-title":"Drug Test Anal"},{"key":"550_CR103","doi-asserted-by":"publisher","first-page":"174","DOI":"10.14701\/ahbps.2019.23.2.174","volume":"23","author":"C Woodward","year":"2019","unstructured":"Woodward C, Smith J, Acreman D, Kumar N. Hepatocellular carcinoma in body builders; an emerging rare but serious complication of androgenic anabolic steroid use. Ann Hepatobiliary Pancreat Surg. 2019;23:174\u20137.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"550_CR104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drugpo.2018.02.011","volume":"55","author":"R Brennan","year":"2018","unstructured":"Brennan R, Wells J, Van Hout MC. \u201cBlood letting\u201d-Self-phlebotomy in injecting anabolic-androgenic steroids within performance and image enhancing drug (PIED) culture. Int J Drug Policy. 2018;55:47\u201350.","journal-title":"Int J Drug Policy"},{"key":"550_CR105","volume-title":"Image and performance enhancing drugs 2015 survey results","author":"G Bates","year":"2016","unstructured":"Bates G, McVeigh J. Image and performance enhancing drugs 2015 survey results. Liverpool: Centre for Public Health: Liverpool John Moores University; 2016."},{"issue":"4","key":"550_CR106","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1123\/jcsp.2019-0028","volume":"14","author":"H Gilmore","year":"2020","unstructured":"Gilmore H, Shannon S, Leavey G, Dempster M, Gallagher S, Breslin G. Help-seeking beliefs among anabolic androgenic steroid users experiencing side effects: an interpretive phenomenological analysis. J Clin Sport Psychol. 2020;14(4):359\u201375.","journal-title":"J Clin Sport Psychol"},{"key":"550_CR107","volume-title":"Facilitators and barriers to health care access amongst people using image and performance enhancing drugs in wales: findings & outcomes","author":"V Hope","year":"2020","unstructured":"Hope V, Leavey G, Morgan G, Acreman D, Turmer D, Smith J. Facilitators and barriers to health care access amongst people using image and performance enhancing drugs in wales: findings & outcomes. Cardiff: Public Health Wales; 2020."},{"issue":"3\u20134","key":"550_CR108","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.peh.2019.03.001","volume":"6","author":"KJ Mulrooney","year":"2019","unstructured":"Mulrooney KJ, van de Ven K, McVeigh J, Collins R. Commentary: Steroid Madness- has the dark side of anabolic-androgenic steroids (AAS) been over-stated? Perform Enhanc Health. 2019;6(3\u20134):98\u2013102.","journal-title":"Perform Enhanc Health"},{"key":"550_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2019.05.016","volume":"71","author":"J McVeigh","year":"2019","unstructured":"McVeigh J. Engaging with people who use image and performance enhancing drugs: One size does not fit all. Int J Drug Policy. 2019;71:1\u20132.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"550_CR110","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0091450917694268","volume":"44","author":"R Zahnow","year":"2017","unstructured":"Zahnow R, McVeigh J, Ferris J, Winstock A. Adverse effects, health service engagement, and service satisfaction among anabolic androgenic steroid users. Contemp Drug Probl. 2017;44(1):69\u201383.","journal-title":"Contemp Drug Probl"},{"key":"550_CR111","doi-asserted-by":"publisher","unstructured":"Henning A, Andreasson J. Preventing, producing, or reducing harm? Fitness doping risk and enabling environments. Drugs Educ Prev Policy. 2020:1\u201310. https:\/\/doi.org\/10.1080\/09687637.2020.1865273.","DOI":"10.1080\/09687637.2020.1865273"},{"key":"550_CR112","doi-asserted-by":"publisher","first-page":"204209861985529","DOI":"10.1177\/2042098619855291","volume":"10","author":"SA Hill","year":"2019","unstructured":"Hill SA, Waring WS. Pharmacological effects and safety monitoring of anabolic androgenic steroid use: differing perceptions between users and healthcare professionals. Ther Adv Drug Saf. 2019;10:2042098619855291.","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"550_CR113","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/09687637.2019.1705763","volume":"27","author":"O Harvey","year":"2020","unstructured":"Harvey O, Parrish M, van Teijlingen E, Trenoweth S. Support for non-prescribed anabolic androgenic steroids users: a qualitative exploration of their needs. Drug-Educ Prev Polic. 2020;27(5):377\u201386.","journal-title":"Drug-Educ Prev Polic"},{"issue":"3","key":"550_CR114","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/09503153.2019.1653450","volume":"32","author":"O Harvey","year":"2019","unstructured":"Harvey O, Parrish M. Social work implications of anabolic-androgenic steroid use, particularly among young people: a literature review. Practice. 2019;32(3):209\u201328.","journal-title":"Practice"},{"issue":"4","key":"550_CR115","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/09503153.2018.1510480","volume":"31","author":"O Harvey","year":"2018","unstructured":"Harvey O. \u2018Shades of Grey\u2019: the ethics of social work practice in relation to un-prescribed anabolic androgenic steroid use. Practice. 2018;31(4):239\u201358.","journal-title":"Practice"},{"key":"550_CR116","unstructured":"SDF Working Group on IPEDS. Image and Performance Enhancing Drugs (IPEDS) in Scotland. SDF; 2018."},{"key":"550_CR117","volume-title":"Building Bodies: Investigating Image and Performance Enhancing Drugs (IPEDs) Use in Scotland","author":"R Miller","year":"2017","unstructured":"Miller R. Building Bodies: Investigating Image and Performance Enhancing Drugs (IPEDs) Use in Scotland. Edinburgh: Scottish Government; 2017."},{"key":"550_CR118","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.drugpo.2016.01.016","volume":"31","author":"J Iversen","year":"2016","unstructured":"Iversen J, Hope VD, McVeigh J. Access to needle and syringe programs by people who inject image and performance enhancing drugs. Int J Drug Policy. 2016;31:199\u2013200.","journal-title":"Int J Drug Policy"},{"key":"550_CR119","doi-asserted-by":"publisher","first-page":"i1889","DOI":"10.1136\/bmj.i1889","volume":"353","author":"J McVeigh","year":"2016","unstructured":"McVeigh J, Kimergard A, Bates G, Hope VD, Ncube F. Harm reduction interventions should encompass people who inject image and performance enhancing drugs. BMJ. 2016;353:i1889.","journal-title":"BMJ"},{"key":"550_CR120","volume-title":"Human enhancement drugs","author":"G Bates","year":"2019","unstructured":"Bates G, Backhouse S. Preventing image and performance enhancing drug use: it\u2019s not all chalk and talk. In: Van de Ven K, Mulrooney K, McVeigh J, editors. Human enhancement drugs. Abingdon: Routledge; 2019."},{"issue":"11","key":"550_CR121","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1177\/1359105317737607","volume":"24","author":"G Bates","year":"2019","unstructured":"Bates G, Begley E, Tod D, Jones L, Leavey C, McVeigh J. A systematic review investigating the behaviour change strategies in interventions to prevent misuse of anabolic steroids. J Health Psychol. 2019;24(11):1595\u2013612.","journal-title":"J Health Psychol"},{"key":"550_CR122","volume-title":"Human enhancement drugs","author":"R Brennan","year":"2019","unstructured":"Brennan R, Wells JSG, Van Hout MC. \u201cBeauty through the eye of a needle\u201d\u2014an online study of the practices and beliefs of people who inject performance and image enhancing drugs (PIEDs). In: Van de Ven K, Mulrooney K, McVeigh J, editors. Human enhancement drugs. Abingdon: Routledge; 2019."},{"issue":"10","key":"550_CR123","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1111\/bph.14995","volume":"177","author":"C Mullen","year":"2020","unstructured":"Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: an update. Br J Pharmacol. 2020;177(10):2180\u201398.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"550_CR124","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1186\/s12889-019-7288-x","volume":"19","author":"O Harvey","year":"2019","unstructured":"Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access. BMC Public Health. 2019;19(1):1024.","journal-title":"BMC Public Health"},{"key":"550_CR125","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drugalcdep.2018.11.021","volume":"195","author":"R Glass","year":"2019","unstructured":"Glass R, Hope VD, Njoroge J, Edmundson C, Smith J, McVeigh J, et al. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012\u201315. Drug Alcohol Depend. 2019;195:40\u20134.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"550_CR126","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/dar.13198","volume":"40","author":"VD Hope","year":"2020","unstructured":"Hope VD, McVeigh J, Begley E, Glass R, Edmundson C, Heinsbroek E, et al. Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs. Drug Alcohol Rev. 2020;40(4):586\u201396.","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"550_CR127","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/hsc.12326","volume":"25","author":"R Brennan","year":"2017","unstructured":"Brennan R, Wells JSG, Van Hout MC. The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review. Health Soc Care Community. 2017;25(5):1459\u2013531.","journal-title":"Health Soc Care Community"},{"issue":"1","key":"550_CR128","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.peh.2017.11.001","volume":"6","author":"R Brennan","year":"2018","unstructured":"Brennan R, Wells JSG, Van Hout MC. \u201cRaw juicing\u201d \u2013 an online study of the home manufacture of anabolic androgenic steroids (AAS) for injection in contemporary performance and image enhancement (PIED) culture. Perform Enhanc Health. 2018;6(1):21\u20137.","journal-title":"Perform Enhanc Health"},{"key":"550_CR129","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bodyim.2016.06.005","volume":"18","author":"C Edwards","year":"2016","unstructured":"Edwards C, Tod D, Molnar G, Markland D. Predicting muscularity-related behavior, emotions, and cognitions in men: The role of psychological need thwarting, drive for muscularity, and mesomorphic internalization. Body Image. 2016;18:108\u201312.","journal-title":"Body Image"},{"key":"550_CR130","volume-title":"Beyond the muscles: exploring the meaning and role of muscularity in identity","author":"I Cranswick","year":"2019","unstructured":"Cranswick I. Beyond the muscles: exploring the meaning and role of muscularity in identity. Liverpool: Liverpool John Moores University; 2019."},{"key":"550_CR131","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugalcdep.2017.06.018","volume":"179","author":"VD Hope","year":"2017","unstructured":"Hope VD, McVeigh J, Smith J, Glass R, Njoroge J, Tanner C, et al. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012\u201315. Drug Alcohol Depend. 2017;179:83\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"550_CR132","unstructured":"Bates G, Hope V, McVeigh J. HIV among people using anabolic steroids in the United Kingdom: an overview. HIV Nursing: Sharing best practice in HIV care. 2017;17(20-23)."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00550-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T03:58:18Z","timestamp":1699675098000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00550-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00550-z","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"107"}}